CALL US:022-2204 0015 / 16 / 17   isa@saffronmedia.in
HOME NEWS INGREDIENT MART EVENTS TOPICS INTERVIEW EDIT
 
News
 
Our Bureau, Mumbai November 16 , 2020
Dalmia Healthcare will be announcing the launch of a polyherbal combination of 15 herbs called Astha-15, developed by its research arm Dalmia Centre for Research and Development (DCRD), for the treatment of COVID-19 along with standard care approved as per Ayush/Indian Council of Medical Research (ICMR) guidelines.

Dalmia’s Astha-15 will be the first ayurvedic drug and an indigenous formulation from India in the global market addressing the respiratory disorders in COVID-19.

Dalmia Healthcare had earlier sought approval to conduct a clinical trial of Astha-15 to evaluate the efficacy and safety of polyherbal combination for the treatment of COVID-19 along with standard care approved as per Ayush/ICMR guidelines.

After two successful phases, phase III trial was conducted on 120 subjects at multi-centric sites viz. JNUIMSRC, Jaipur, Govt. Medical College & Government General Hospital, Srikakulam (Old RIMSGGH) and RGMC & CSMH, Thane by following the regulatory guidelines of Ayush and the Informed Consent Declaration, Insurance Terms and Hospital Ethics Committee approvals which are registered at DCGI to perform the clinical trial.

Sanjay Dalmia, chairman, Dalmia Group of Companies said, “We are happy to announce that the outcome of the clinical trial showed that Astha-15 has significantly reduced the cough and wheezing, improved the respiratory rate and aid in the speedy recovery of COVID-19 patients with the improvement of quality of life during the treatment cycle.”

The medicine acts as a bronchodilator, decongestant, anti-inflammatory and lung detoxifier. It helps in eliminating the infection and regulating the allergic reactions. This has a specific action on the mucosa of the respiratory tract and the muscular walls of the lungs that act as the airways. It has an anti-inflammatory effect which reduces inflammation and congestion inside the lungs. Its continuous use reduces the damage on the lungs and the muscular walls and brings out a significant reversal in their dysfunction. All these disorders which have been found in COVID19 patients have been confirmed to be treated by Astha-15.

Astha-15 will be made available in the first phase through prescriptions written for mild and moderate COVID patients undergoing treatment in COVID Hospitals. Dalmia Healthcare would be applying for permission/approval of Astha-15 usage in allopathic hospitals, as per the procedure in each hospital.

Share This Story

Leave a Reply
Your name (required)   Your email (required)
         
Website (required)
   
CommenT
 
Enter Code (Required)

 

 

 
INGREDIENT MART

RECENT NEWS

TOPICS
The healthy snacks segment is estimated to be around 2 per cent of the overall snacks market in India, according to expe ...

 

MAIN LINKS OUR SERVICES OTHER PRODUCTS ONLINE MEDIA  
 
About Us
Contact Us
News Archives
 

Product Finder
Features and Articles
News
 
Chronicle Pharmabiz
Food & Bevergae News
Ingredients South Asia
 
Media Information
Rate Card
Advertise
 
 
Copyright © 2013 Saffron Media Pvt Ltd. All Rights Reserved.
Best View in Internet Explorer(9.0) or Firefox(26.0)